Contact
searchSearch
HMP Global

Advertisement

ADVERTISEMENT

Musculoskeletal Disease Topic Center

Musculoskeletal Interventions

Jack Jennings, MD, PhD, Washington University in St Louis
Videos
Treatment of Primary and Metastatic Sarcoma
02/06/2024
At the 2024 SIO Annual Meeting, Jack Jennings, MD, PhD, discussed the role of the interventional oncologist when treating primary or metastatic sarcomas of the bone or soft tissue.
At the 2024 SIO Annual Meeting, Jack Jennings, MD, PhD, discussed the role of the interventional oncologist when treating primary or metastatic sarcomas of the bone or soft tissue.
At the 2024 SIO Annual Meeting,...
02/06/2024
IO Learning
Dr. Wylie Foss, MD, Dr. Steven Yevich, MD
Practical Tips and Tricks
Transvertebral Access for Ablation of Metastasis Located Anterior to the Spine
06/30/2023
This case report and review highlights the case of a 45-year-old woman was diagnosed with stage IV sigmoid colon adenocarcinoma. Dr. Wylie Foss and Dr. Steven Yevich share their insights into transvertebral access for ablation of metastasis...
This case report and review highlights the case of a 45-year-old woman was diagnosed with stage IV sigmoid colon adenocarcinoma. Dr. Wylie Foss and Dr. Steven Yevich share their insights into transvertebral access for ablation of metastasis...
This case report and review...
06/30/2023
IO Learning
Dr Alan Sag
SIO2023 Highlights
Current Trends and Future Directions in Musculoskeletal Interventions
01/20/2023
Alan Alper Sag, MD, Assistant Professor, Duke Interventional Radiology and Duke Orthopaedic Surgery, discusses the current state and future of musculoskeletal interventions.
Alan Alper Sag, MD, Assistant Professor, Duke Interventional Radiology and Duke Orthopaedic Surgery, discusses the current state and future of musculoskeletal interventions.
Alan Alper Sag, MD, Assistant...
01/20/2023
IO Learning
Callstrom CIO
Musculoskeletal Oncologic Interventions: 2022 Year in Review
Matthew Callstrom, MD, PhD presents notable 2022 studies on musculoskeletal interventions at the Symposium on Clinical Interventional Oncology.
01/06/2023
News
New Study Shows Recently Diagnosed Adult Cancer Survivors at Higher Risk for Bone Fractures
11/03/2022
ATLANTA, November 3, 2022 — Adult cancer survivors, particularly those diagnosed within five years and/or have a history of chemotherapy, have an increased risk for bone fractures, specifically pelvic and vertebral fractures, compared to...
ATLANTA, November 3, 2022 — Adult cancer survivors, particularly those diagnosed within five years and/or have a history of chemotherapy, have an increased risk for bone fractures, specifically pelvic and vertebral fractures, compared to...
ATLANTA, November 3, 2022...
11/03/2022
IO Learning
Duncan
CIO2022 Highlights
Irreversible Electroporation for Recurrent Pelvic Metastases
10/27/2022
Duncan A. Stevens discusses his CIO2022 abstract, "CIO 2022-20 Irreversible Electroporation for Recurrent Pelvic Metastases: Case Series and Literature Review."
Duncan A. Stevens discusses his CIO2022 abstract, "CIO 2022-20 Irreversible Electroporation for Recurrent Pelvic Metastases: Case Series and Literature Review."
Duncan A. Stevens discusses his...
10/27/2022
IO Learning
CIO 2022-14 Radiofrequency Ablation in Osteoid Osteomas of Typical and Atypical Presentations
Purpose: To evaluate the technical and clinical success and complications of radiofrequency ablation (RFA) in osteoid osteomas with typical and atypical presentations.
10/18/2022
CIO 2022-16 Preoperative Embolization in Bone and Soft Tissue Pelvic Tumors: An Experience in a Tertiary Care Oncology Center
Purpose: The purpose of this study is to evaluate the role of preoperative embolization in surgical management of patients with pelvic tumors.
10/18/2022
CIO 2022-20 Irreversible Electroporation for Recurrent Pelvic Metastases: Case Series and Literature Review
Purpose: Irreversible electroporation (IRE) is a nonthermal ablative technique that has potential safety advantages over thermal ablation in the treatment of patients with tumors near cri...
10/18/2022
News
New Liquid Embolic Multi-Center Trial Successfully Enrolls Final Patient
09/01/2022
GPX® Trial Completes Enrollment Demonstrating Successful Tumor Uses and Other Applications
GPX® Trial Completes Enrollment Demonstrating Successful Tumor Uses and Other Applications
GPX® Trial Completes Enrollment...
09/01/2022
IO Learning
Osteocool™ RF Ablation System for Bone Metastases: Clinically Significant Pain Relief and Improved Quality of Life
Jonathan M. Morris, MD discusses the latest research on radiofrequency ablation for painful bone metastases with the OsteoCool System.
02/18/2022

Subscribe

IO Learning Newsletter

News

News
New Study Shows Recently Diagnosed Adult Cancer Survivors at Higher Risk for Bone Fractures
11/03/2022
ATLANTA, November 3, 2022 — Adult cancer survivors, particularly those diagnosed within five years and/or have a history of chemotherapy, have an increased risk for bone fractures, specifically pelvic and vertebral fractures, compared to...
ATLANTA, November 3, 2022 — Adult cancer survivors, particularly those diagnosed within five years and/or have a history of chemotherapy, have an increased risk for bone fractures, specifically pelvic and vertebral fractures, compared to...
ATLANTA, November 3, 2022...
11/03/2022
IO Learning
News
New Liquid Embolic Multi-Center Trial Successfully Enrolls Final Patient
09/01/2022
GPX® Trial Completes Enrollment Demonstrating Successful Tumor Uses and Other Applications
GPX® Trial Completes Enrollment Demonstrating Successful Tumor Uses and Other Applications
GPX® Trial Completes Enrollment...
09/01/2022
IO Learning
News
Novel Endovascular Robotic Surgical System Reaches Midpoint of Pivotal Clinical Trial
09/20/2024
The ACCESS-PVI trial of LIBERTY® Endovascular Robotic Surgical System has enrolled and completed follow-up for 50% of patients.
The ACCESS-PVI trial of LIBERTY® Endovascular Robotic Surgical System has enrolled and completed follow-up for 50% of patients.
The ACCESS-PVI trial of LIBERTY®...
09/20/2024
IO Learning
News
Histotripsy Demonstrates Technical Success, Safety for Primary and Metastatic Liver Tumors
09/04/2024
According to results from the parallel #HOPE4LIVER trials, the novel ablation technique of histotripsy met coprimary end points for technical success and safety among patients with primary and metastatic liver tumors.
According to results from the parallel #HOPE4LIVER trials, the novel ablation technique of histotripsy met coprimary end points for technical success and safety among patients with primary and metastatic liver tumors.
According to results from the...
09/04/2024
IO Learning
News
Sorafenib Plus Transarterial Chemoembolization Improves Survival Outcomes, Response Among Patients With Recurrent Hepatocellular Carcinoma
07/29/2024
According to a phase 3 trial, the addition of sorafenib to TACE improved survival outcomes and response among patients with recurrent intermediate-stage hepatocellular carcinoma after R0 initial hepatectomy and microvascular invasion.
According to a phase 3 trial, the addition of sorafenib to TACE improved survival outcomes and response among patients with recurrent intermediate-stage hepatocellular carcinoma after R0 initial hepatectomy and microvascular invasion.
According to a phase 3 trial,...
07/29/2024
Oncology
News
Thermal Ablation Over Surgical Resection for Patients With Smaller Colorectal Liver Metastases
07/18/2024
According to the phase 3 COLLISION trial, thermal ablation for smaller colorectal liver metastases reduced morbidity and mortality without compromising survival outcomes compared to surgical resection.
According to the phase 3 COLLISION trial, thermal ablation for smaller colorectal liver metastases reduced morbidity and mortality without compromising survival outcomes compared to surgical resection.
According to the phase 3...
07/18/2024
IO Learning
News
Manageable Safety Across Treatment Periods for Durvalumab, Bevacizumab, and TACE Regimen Among Patients With Unresectable Hepatocellular Carcinoma
07/17/2024
According to a post-hoc, exploratory analysis of safety by treatment period in the EMERALD-1 study, durvalumab plus bevacizumab plus transarterial chemoembolization had a manageable safety profile across both treatment periods among patients...
According to a post-hoc, exploratory analysis of safety by treatment period in the EMERALD-1 study, durvalumab plus bevacizumab plus transarterial chemoembolization had a manageable safety profile across both treatment periods among patients...
According to a post-hoc,...
07/17/2024
IO Learning
News
Transit Scientific Announces First Worldwide Case Performed with Innovative Embolic-Delivery Microcatheter
07/09/2024
Transit Scientific Press Release Park City, Utah USA, July 9, 2024 – Transit Scientific, a Utah-based medical device company specializing in innovative solutions for vascular procedures, proudly announces the successful debut of XO...
Transit Scientific Press Release Park City, Utah USA, July 9, 2024 – Transit Scientific, a Utah-based medical device company specializing in innovative solutions for vascular procedures, proudly announces the successful debut of XO...
Transit Scientific Press...
07/09/2024
Vascular Disease Management
Imaging Systems
University Hospitals Cleveland, Siemens Healthineers in New Alliance to Improve Oncology, Cardiovascular and Neurovascular Care for Patients
05/08/2024

Siemens Healthineers and University Hospitals Cleveland News

Siemens Healthineers and University H...
The new alliance will enhance cardiovascular services of the UH Harrington Heart & Vascular Institute with the world’s first clinically available photon-counting CT scanner and the new dual-source CT scanner.
The new alliance will enhance cardiovascular services of the UH Harrington Heart & Vascular Institute with the world’s first clinically available photon-counting CT scanner and the new dual-source CT scanner.
The new alliance will enhance...
05/08/2024
Cath Lab Digest
News
Histotripsy Treatment for Primary and Metastatic Liver Tumors
04/25/2024
At the 2023 CIRSE Annual Meeting, first results from the #HOPE4LIVER trial evaluating histotripsy for primary and metastatic liver tumors were reported.
At the 2023 CIRSE Annual Meeting, first results from the #HOPE4LIVER trial evaluating histotripsy for primary and metastatic liver tumors were reported.
At the 2023 CIRSE Annual...
04/25/2024
IO Learning
News
First-of-Its-Kind Surgical Foam Technology Improves Operating Room Workflow
04/24/2024

Syntervention Press Release

Syntervention Press Release
Rocky Mount, North Carolina, USA, April 24, 2024 — Syntervention, Inc., a medical device company focused on meeting critical needs in the healthcare space, announces the impact of using its SWICKER® Radiopaque Surgical Foam Sponge in open...
Rocky Mount, North Carolina, USA, April 24, 2024 — Syntervention, Inc., a medical device company focused on meeting critical needs in the healthcare space, announces the impact of using its SWICKER® Radiopaque Surgical Foam Sponge in open...
Rocky Mount, North Carolina,...
04/24/2024
EP Lab Digest
News
Fluidx Medical Reveals New Embolic Platform for Internal Bleeding, Tumor Treatment, and Other Uses
11/30/2023
Salt Lake City (UT) – Fluidx Medical today released information about their new ULTRA™ embolic platform designed to make therapeutic embolization procedures safer, better, and faster.   Embolization is a minimally invasive...
Salt Lake City (UT) – Fluidx Medical today released information about their new ULTRA™ embolic platform designed to make therapeutic embolization procedures safer, better, and faster.   Embolization is a minimally invasive...
Salt Lake City (UT) – Fluidx...
11/30/2023
Vascular Disease Management

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use

Advertisement

Advertisement